Top

International Journal of Colorectal Disease

Published in:

01-08-2007 | Original Article

Tumor budding as a prognostic marker in stage-III rectal carcinoma

Authors: Hong-Jo Choi, Ki-Jae Park, Jong-Sok Shin, Mee-Sook Roh, Hyuk-Chan Kwon, Hyung-Sik Lee

Published in: International Journal of Colorectal Disease | Issue 8/2007

Abstract

Background and aim

Tumor budding along the invasive margin is known to be associated with biological behavior in colorectal carcinoma. The aims of this study were to explore if the semiquantitative assessment of tumor budding in rectal cancers correlates with oncological behavior and to appraise if the tumor budding is valid as a pathological parameter in distinguishing tumors with higher malignancy potential from those with lower one for prognostic stratification.

Materials and methods

Surgical specimens from 244 patients with well- or moderately differentiated rectal carcinoma were retrieved to assess the intensity of tumor budding at the invasive margin. Intensities were divided semiquantitatively into four groups based on quartiles, and the 5-year disease-free survivals (DFS) were analyzed to search for a cutoff point of prognostic stratification.

Results

The cutoff of the intensity considered to be the best indicator for dividing patients into subgroups with different DFS was between quartiles 3 and 4, but this survival difference in subgroups in either side of the cutoff was significant only in stage-III disease [5-year DFS, 62.1 vs 35.1%; p = 0.0023; 95% confidence interval (CI), 0.1824–0.6919]. Based on multivariate analysis, the intensity of budding proved to be an independent variable associated with DFS (hazard ratio, 2.005; p = 0.0086; 95% CI, 1.021–3.934). When scores were given to grade of budding (lower, 0; higher, 1) and N stage (N1, 0; N2, 1) in stage III, a better prognostic stratification in terms of the 5-year DFS was obtained than the American Joint Committee on Cancer nodal staging only (0 vs 1 vs 2, 66.5 vs 42.6 vs 29.2%; p = 0.0101).

Conclusions

Quantitative assessment of tumor budding is a reliable biological prognostic variable to identify higher malignancy potential. Scoring system using tumor budding and N stage showed better prognostic stratification in stage-III rectal carcinoma. A prospective evaluation would confirm the clinical significance of tumor budding for prognostic stratification.

Jass JR, Morson BC (1987) Reporting colorectal cancer. Br J Clin Pathol 40:1016–1023CrossRef

Fielding LP, Phillips RK, Fry JS, Hittinger R (1986) Prediction of outcome after curative resection for large bowel cancer. Lancet 18:904–907CrossRef

Michelassi F, Ayala JJ, Balestracci T, Goldberg R, Chappell R, Block GE (1991) Verification of a new clinicopathologic staging system for colorectal adenocarcinoma. Ann Surg 214:11–18PubMed

Harrison JC, Dean PJ, El-Zeky F, Vander Zwaag R (1994) From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol 25:498–505PubMedCrossRef

Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M (1989) An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 63:539–543PubMedCrossRef

Hase K, Shatney C, Johnson D, Trollope M, Vierra M (1993) Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 36:627–635PubMedCrossRef

Gabbert H (1985) Mechanism of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev 4:293–309PubMedCrossRef

Okuyama T, Oya M, Ishikawa H (2003) Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma. J Surg Oncol 83:42–47PubMedCrossRef

Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC (2002) Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40:127–132PubMedCrossRef

10.

Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163–170PubMed

11.

Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187–220

12.

Nowell PC (1986) Mechanisms of tumor progression. Cancer Res 46:2203–2207PubMed

13.

Frost P, Levin B (1992) Clinical implications of metastatic process. Lancet 339:1458–1461PubMedCrossRef

14.

Gabbert H (1985) Mechanism of tumor invasion: evidence from in vivo observations. Cancer Metastasis Rev 4:293–309PubMedCrossRef

15.

Sordat I, Rousselle P, Chaubert P, Petermann O, Aberdam D, Bosman FT, Sordat B (2000) Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer 88:708–717PubMedCrossRef

16.

Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K (1995) Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 55:4132–4139PubMed

17.

Masaki T, Goto A, Sugiyama M, Matsuoka H, Abe N, Sakamoto A, Atomi Y (2001) Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma. Cancer 92:2539–2546PubMedCrossRef

18.

Fujiya M, Watari J, Ashida T, Honda M, Tanabe H, Fujiki T, Saitoh Y, Kohgo Y (2001) Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer. Jpn J Cancer Res 92:1074–1081PubMed

19.

Ueno H, Mochizuki H, Shinto E, Hashiguchi Y, Hase K, Talbot IC (2002) Histologic indices in biopsy specimens for estimating the probability of extended local spread in patients with rectal carcinoma. Cancer 94:2882–2891PubMedCrossRef

20.

Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T (2000) Indicators for treatment strategies of colorectal liver metastases. Ann Surg 231:59–66PubMedCrossRef

21.

Park KJ, Choi HJ, Roh MS, Kwon HC, Kim C (2005) Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 48:1597–1602PubMedCrossRef

22.

Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC (2004) A new prognostic staging system for rectal cancer. Ann Surg 240:832–839PubMedCrossRef

23.

Deans GT, Heatley M, Anderson N, Patterson CC, Rowlands BJ, Parks TG, Spence RA (1994) Jass’ classification revisited. J Am Coll Surg 179:11–17PubMed

24.

Jass JR, Ajioka Y, Allen JP, Chan YF, Cohen RJ, Nixon JM, Radojkovic M, Restall AP, Stables SR, Zwi LJ (1996) Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology 28:543–548PubMedCrossRef

25.

Sternberg A, Sibirsky O, Cohen D, Blumenson LE, Petrelli NJ (1999) Validation of a new classification system for curatively resected colorectal adenocarcinoma. Cancer 86:782–792PubMedCrossRef

Title: Tumor budding as a prognostic marker in stage-III rectal carcinoma
Authors: Hong-Jo Choi
Ki-Jae Park
Jong-Sok Shin
Mee-Sook Roh
Hyuk-Chan Kwon
Hyung-Sik Lee
Publication date: 01-08-2007
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 8/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-006-0249-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tumor budding as a prognostic marker in stage-III rectal carcinoma

Abstract

Background and aim

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aim

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2007

Disseminated Klebsiella pneumoniae infection after hemorrhoidectomy

Colonic toxicity of antidepressants: an unusual case of a 48-year-old patient with transient ischemic colitis

Colony-stimulating factor-1 receptor gene polymorphisms and Crohn’s disease

More than just skin deep!

A novel MSH2 mutation in a Chinese family with hereditary non-polyposis colorectal cancer

Endosonographic and manometric evaluation of internal anal sphincter in patients with chronic anal fissure and its correlation with clinical outcome after topical glyceryl trinitrate therapy